Associate Professor, Pathology-Brigham and Women's Hospital, Harvard Medical School
Pathology
Dr. Neal I. Lindeman, MD
|
|
Give Review
Doctor Neal I. Lindeman, MD works in the field of Pathology. He studied medicine at University of Rochester School of Medicine and Dentistry. Neal Lindeman is also a published doctor. He has 66 paper published. The most recent paper is: Survival with early diagnosis of invasive gastric mucormycosis in a heart transplant patient. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
- Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-κB regulatory genes.
- Marketing of personalized cancer care on the web: an analysis of internet websites.
- Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.
- Novel molecular insights from routine genotyping of colorectal carcinomas.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma.
- BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
- Targeted Genomic Analysis of Müllerian Adenosarcoma.
- Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients.
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
- Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Detection of MYD88 L265P in peripheral blood of patients with waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
- Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
- An improved algorithm for activated protein C resistance and factor v leiden screening.
- Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung.
- A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia.
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, Int...
- Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas.
- MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy, and other B-cell Lymphoproliferative Disorders using Conventional and Quantitative Allele-Sp...
- The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer.
- Molecular diagnostics of lung cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: technology in rapid evolution.
- The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations.
- No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from h&e-stained archival tissue sections.
- Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas.
- EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.
- Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.
- Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
- Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
- EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.
- Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature.
- Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
- Selecting automation for the clinical chemistry laboratory.
- Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
- Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
- Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
- Multifocal dural enhancement associated with temporal arteritis.
- Survival with early diagnosis of invasive gastric mucormycosis in a heart transplant patient.
- Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglob...
- Immunosuppressant monitoring can be performed by UPLC-Tandem Mass Spectrometry in half the time needed for conventional HPLC-Tandem Mass Spectrometry, with comparable ...
- LKB1 modulates lung cancer differentiation and metastasis.
- Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
- One patient, two lymphomas. Simultaneous primary gastric marginal zone lymphoma and primary duodenal follicular lymphoma.
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
- Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection.
- Effectiveness of sequencing connexin 26 (GJB2) in cases of familial or sporadic childhood deafness referred for molecular diagnostic testing.
- Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or ...
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
- A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
- A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
- Copy number variants and pharmacogenomics.
- Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose ...
- MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
- Characterizing the cancer genome in lung adenocarcinoma.
- Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
- EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
- No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.
- Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
- Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male.
- A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
- Polylactide-cyclosporin A nanoparticles for targeted immunosuppression.
- A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
- Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study.
- KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Schools
University Of Rochester
University Of California Sf
Brigham and Women39s Hospital
Doctors Specialties
- Molecular Genetic Pathology
- Pathology
Accepted Insurances
Education
-
UCSF -
University of Rochester School of Medicine and Dentistry
Hospital
-
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699791681 |
| Last Name Of The Provider | LINDEMAN |
| First Name Of The Provider | NEAL |
| View All |
Similar Doctors
|
|
Dr. Robert P. Hasserjian, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Charlotte I. Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matija Snuderl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dipti P. Sajed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Valentina Nardi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chan-Shik Park, MD |
|
|
Dr. Alanna J. Church, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaohua Qian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuji Ogino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janina A. Longtine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. French, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deborah A. Dillon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruben D. Carrasco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madhu Dahiya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew H. Beck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra R. Cerda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nada A. Farhat, MD |